Registry of Genetic Changes in Oropharyngeal Cancer in Taiwan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to utilize next-generation sequencing (NGS) technology to identify genomic alterations in oropharyngeal squamous cell carcinoma (OPSCC) among Taiwanese patients, both HPV positive and negative. By collecting tumor tissues and clinical data, the study seeks to develop novel biomarkers and inform the design of future clinical trials or translational research. The research will address the unclear differences in genomic profiling between the two OPSCC subgroups, contributing to precision medicine approaches in cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ages 20 and above
2. Pathological reported as squamous cell carcinoma of head and neck
3. Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)
4. Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)
5. Recurrence status is defined as the reappearance of the disease occurring more than 6 months following curative surgery and/or chemoradiotherapy in the recurrence subgroup
6. Willingness to provide archival or newly obtained tumor tissues for current study proposal
7. Life expectancy more than 3 months
8. Patients fully understand the protocol with the willingness to have regular follow-up

Exclusion criteria

1. Inability to cooperate by providing a complete medical history
2. No available tumor tissues for genetic testing
3. Undesirable compliance
4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded

Where it's running

• Kaohsiung Medical University Chung-Ho Memorial Hospital
  Kaohsiung City, Taiwan Recruiting
• Kaohsiung Veterans General Hospital
  Kaohsiung City, Taiwan Recruiting
• China Medical University Hospital
  Taichung, Taiwan Recruiting
• Taichung Veterans General Hospital
  Taichung, Taiwan Recruiting
• National Cheng Kung University Hospital
  Tainan, Taiwan Recruiting
• Pei-Jen Alex Lou
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Pei-Jen Lou, MD, PhD — National Taiwan University Hospital
• Study coordinator: Shang-Hung Chen, MD.PhD
• Email: bryanchen@nhri.edu.tw
• Phone: 886 (06) 7000123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Lowering nodal and primary tumor radiation dose in HPV-positive oropharyngeal cancer

  This phase II study tests whether reducing radiation doses to regions without visible cancer, while keeping the main tumor dose the same, can treat HPV-positive OPSCC with fewer side effects.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07497607

• Selective dose reduction of neck radiation in HPV-associated oropharyngeal cancer

  This trial tests whether lowering radiation doses to certain neck lymph nodes or gross disease areas is safe and can reduce side effects for adults with HPV-related oropharyngeal cancer.

  Recruiting at 4 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 3 other locations · NCT07418034

• Comparing dual-energy CT and MRI for staging oral and oropharyngeal squamous cell carcinoma

  This will test whether 40 keV dual-energy CT can replace a contrast-enhanced neck and facial MRI for staging adults with oral or oropharyngeal squamous cell carcinoma.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07343271

• Personalized compartment-sparing postoperative radiation for head and neck cancer

  This trial tests whether targeted, compartment-sparing postoperative radiation can reduce side effects while keeping cancer control for people with surgically treated head and neck squamous cell carcinoma.

  Recruiting at 3 sites Phase 2 Insel Gruppe AG, University Hospital Bern · Basel and 2 other locations · NCT07058805

• Shorter radiation after trans-oral robotic surgery for HPV-related oropharyngeal cancer

  This trial tests whether giving a shorter course of radiation after trans-oral robotic surgery helps people with HPV-related oropharyngeal cancer have better quality of life.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT07044635

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.